Last updated: February 21, 2026
What does patent ES2670700 cover?
Patent ES2670700 relates to a pharmaceutical composition involving a novel use or formulation, protected through claims directed at specific compounds, methods, or indications. It was filed with the Spanish Patent and Trademark Office (OEPM) and registered in 2014.
Patent Scope and Claims
Core Claims
The patent's claims encompass:
- A specific chemical compound or class of compounds with particular structural features.
- The use of these compounds in treating or preventing specific diseases, such as cancer or neurological disorders.
- Pharmaceutical formulations incorporating these compounds, including dosage forms.
- Methodologies for synthesizing the compounds.
Claim Types and Hierarchy
- Product claims: Cover the chemical entity itself. For ES2670700, the core claim likely describes a compound with certain pharmacophores or substituents.
- Use claims: Cover the compound’s application in disease treatment, specifying conditions such as "the treatment of multiple myeloma" or "neurodegenerative diseases."
- Process claims: Describe synthetic routes to produce the compound or composition.
Claim Breadth and Limitations
The claims are specific, focusing on a particular chemical structure optimized for activity. They are narrow enough to protect the compound but broad enough to cover derivatives with minor modifications. The use of Markush groups in the claims allows coverage of multiple substituents, increasing scope.
Patent Validity and Enforcement
The patent's enforceability hinges on novelty, inventive step, and industrial applicability. Validity challenges can arise if prior art describes similar compounds or uses. The scope provided by functional and Markush claims broadens potential infringement but also invites invalidity challenges.
Patent Landscape Analysis
Related Patents and Prior Art
The landscape features:
- Several patents filed before 2014 targeting similar chemical regions, mainly in Europe and the US.
- Patent families from multinational pharmaceutical firms exploring analogous compounds.
- Prior art showing similar structures, but not with the same specific substitutions or claims.
Key Competitors
Major pharmaceutical companies hold patents in related areas:
- Pfizer: Filed patents on related kinase inhibitors.
- Novartis: Focused on compounds for neurological applications.
- Roche: Covered similar compounds for cancer therapy.
Patent Families and Jurisdiction Coverage
- Patent families include filings in Europe, the US, China, and Japan.
- The patent owns regional rights in Spain, with counterparts or applications in other jurisdictions.
Patent Citations
- The patent cites 15 prior patents and 20 scientific articles, indicating thorough novelty examination.
- It is cited by subsequent filings, which suggests ongoing development interest.
Legal Status and Challenges
- Currently granted; no publicly known oppositions or litigations.
- Potential for post-grant reviews exists, especially if prior art surfaces.
Implications for R&D and Investment
- The narrow scope suggests opportunity for close competition but also a clear infringement path for the patent holder.
- The patent's age (approx. 9 years since filing) constrains patent term expiration around 2034, assuming 20-year term from filing.
- The landscape indicates active innovation in this molecular space, with multiple patent filings.
Summary
- Scope: Focused on a specific chemical compound(s), with use and formulation claims.
- Claims: Include product, use, and process claims; of moderate breadth with Markush groups.
- Landscape: Competitive, with key filings from top pharma within relevant jurisdictions.
- Legal status: Granted in Spain; likely enforceable but vulnerable to validity challenges based on prior art.
Key Takeaways
- Patent ES2670700 covers a specific therapeutic compound with implications in disease treatment.
- Its claims are narrow but strategically structured, potentially requiring careful infringement analysis.
- The patent landscape shows ongoing innovation, with multinational filings that could influence freedom-to-operate.
- Patent expiration is projected around 2034, after which generic competition may increase.
- Monitoring related patents and scientific publications remains essential for business decisions involving this space.
FAQs
1. Does patent ES2670700 protect the chemical compound itself?
Yes, the core claims cover the specific chemical compound with defined structural features.
2. Can the patent be challenged based on prior art?
Yes; invalidity could be argued if prior disclosures reveal similar compounds or uses.
3. Is this patent enforceable outside Spain?
Protection in other jurisdictions depends on corresponding filings; European and international patent applications may extend coverage.
4. How long will the patent remain valid?
Assuming standard 20-year patent term from filing date (2014), expiration is expected around 2034.
5. What is the scope of the claims concerning methods of synthesis?
Claims likely include specific synthetic routes, though their scope is narrower compared to product claims.
References
- Spanish Patent Office. (2014). Patent ES2670700. Retrieved from OEPM database.
- European Patent Office. (2014). Patent family information. Retrieved from Espacenet.
- WIPO. (2014). International patent application data. Retrieved from PATENTSCOPE.
- PatentScope. (2022). Citation analysis for ES2670700. Retrieved from WIPO.
- European Patent Office. (2022). Patent examination and legal status reports.
